Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR

被引:26
|
作者
Schanda, Nicola [1 ]
Sauer, Tim [1 ]
Kunz, Alexander [1 ]
Huckelhoven-Krauss, Angela [1 ]
Neuber, Brigitte [1 ]
Wang, Lei [1 ]
Hinkelbein, Mandy [1 ]
Sedloev, David [1 ]
He, Bailin [1 ]
Schubert, Maria-Luisa [1 ]
Muller-Tidow, Carsten [1 ]
Schmitt, Michael [1 ]
Schmitt, Anita [1 ]
机构
[1] Univ Hosp Heidelberg, Dept Internal Med Hematol Oncol & Rheumatol 5, D-69120 Heidelberg, Germany
关键词
CD19; CAR-T cells; flow cytometry (FACS); polymerase chain reaction (PCR); detection reagent; CAR T-CELLS; ANTIGEN; STRATEGIES; LYMPHOMA; SAFETY;
D O I
10.3390/cells10113208
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Chimeric-antigen-receptor-T (CAR-T) cells are currently revolutionizing the field of cancer immunotherapy. Therefore, there is an urgent need for CAR-T cell monitoring by clinicians to assess cell expansion and persistence in patients. CAR-T cell manufacturers and researchers need to evaluate transduction efficiency and vector copy number for quality control. Here, CAR expression was analyzed in peripheral blood samples from patients and healthy donors by flow cytometry with four commercially available detection reagents and on the gene level by quantitative polymerase chain reaction (qPCR). Flow cytometric analysis of CAR expression showed higher mean CAR expression values for CD19 CAR detection reagent and the F(ab')2 antibody than Protein L and CD19 Protein. In addition, the CD19 CAR detection reagent showed a significantly lower median background staining of 0.02% (range 0.007-0.06%) when compared to the F(ab')2 antibody, CD19 protein and Protein L with 0.80% (range 0.47-1.58%), 0.65% (range 0.25-1.35%) and 0.73% (range 0.44-1.23%). Furthermore, flow cytometry-based CAR-T cell frequencies by CD19 CAR detection reagent showed a good correlation with qPCR results. In conclusion, quality control of CAR-T cell products can be performed by FACS and qPCR. For the monitoring of CAR-T cell frequencies by FACS in patients, CAR detection reagents with a low background staining are preferable.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] CD19.CAR-T Cell Analysis Using Flow Cytometry and PCR
    Schanda, Nicola
    Kunz, Alexander
    Sauer, Tim
    Schubert, Maria-Luisa
    Korell, Felix
    Hueckelhoven-Krauss, Angela
    Neuber, Brigitte
    Hinkelbein, Mandy
    Mueller-Tidow, Carsten
    Schmitt, Michael
    Schmitt, Anita
    BLOOD, 2021, 138
  • [2] Analysis of CD19.CAR-T cells by flow cytometry and PCR
    Schanda, N.
    Kunz, A.
    Sauer, T.
    Schubert, M. -L
    Korell, F.
    Hueckelhoven-Krauss, A.
    Neuber, B.
    Hinkelbein, M.
    Mueller-Tidow, C.
    Schmitt, M.
    Schmitt, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 259 - 259
  • [3] OPTIMIZATION OF CAR-T CD19 MONITORING BY FLOW CYTOMETRY AND QUANTITATIVE PCR (Q PCR)
    Garcia-Ortiz, A.
    Rapado, I
    Encinas, J.
    Maroto-Martin, E.
    Sanchez-Pina, J. M.
    Garrido, V
    Moreno Sanz, L.
    Juarez Rufian, A.
    Rufian Vazquez, L.
    Caceres Garcia, M.
    Paciello, M.
    Alonso, R.
    Cedena, T.
    Valeri, A.
    Martinez Lopez, J.
    HAEMATOLOGICA, 2019, 104 : 164 - 164
  • [4] Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy
    Yang, Mingya
    Wang, Lei
    Ni, Ming
    Neuber, Brigitte
    Wang, Sanmei
    Gong, Wenjie
    Sauer, Tim
    Schubert, Maria-Luisa
    Hueckelhoven-Krauss, Angela
    Xia, Ruixiang
    Ge, Jian
    Kleist, Christian
    Eckstein, Volker
    Sellner, Leopold
    Mueller-Tidow, Carsten
    Dreger, Peter
    Schmitt, Michael
    Schmitt, Anita
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [5] Cyclooxygenase inhibitors exert dual effects in combination with CD19.CAR-T cell immunotherapy
    Han, H.
    Wang, L.
    Yang, M.
    Neuber, B.
    Sauer, T.
    Schubert, M. -L
    Hueckelhoven-Krauss, A.
    Kleist, C.
    Eckstein, V
    Sellner, L.
    Mueller-Tidow, C.
    Dreger, P.
    Schmitt, M.
    Schmitt, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 103 - 103
  • [6] Immunological effects of CD19.CAR-T cell therapy in systemic sclerosis: an extended case study
    Claus, Maren
    Freitag, Merle
    Ewald, Meike
    Rodon, Lea
    Deicher, Franca
    Watzl, Carsten
    Kolb, Philipp
    Lorenz, Hanns-Martin
    Schmitt, Michael
    Merkt, Wolfgang
    ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
  • [7] Oligoclonal expansion and loss of cytotoxic functionality of CAR-T cells in a DLBCL patient after CD19.CAR-T cell therapy
    Mueller, F.
    Schwingen, N. R.
    Eisenhauer, N.
    Aigner, M.
    Schletter, M.
    Lutzny-Geier, G.
    Lischer, C.
    Guese, E.
    Gebhard, C.
    Rehli, M.
    Gonzalez, Vera J.
    Eckstein, M.
    Wiesmueller, M.
    Erber, R.
    Bruns, H.
    Mackensen, A.
    Voelkl, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 73 - 74
  • [8] Single-cell Transcriptome Analysis and clonal Kinetics in a Patient after CD19.CAR-T Cell Therapy
    Lischer, C.
    Eisenhauer, N.
    Aigner, M.
    Jacobs, B.
    Schletter, M.
    Gebhard, C.
    Rehli, M.
    Bruns, H.
    Muller, F.
    Mackensen, A.
    Gonzalez, Vera J.
    Volkl, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 125 - 125
  • [9] T-cell crossmatching: A cytotoxic method with sensitivity and specificity close to that of flow cytometry.
    Steen, SI
    Abtahi, S
    Inokuchi, S
    HUMAN IMMUNOLOGY, 1997, 55 : 86 - 86
  • [10] Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+systemic sclerosis
    Merkt, Wolfgang
    Freitag, Merle
    Claus, Maren
    Kolb, Philipp
    Falcone, Valeria
    Roehrich, Manuel
    Rodon, Lea
    Deicher, Franca
    Andreeva, Ivana
    Tretter, Theresa
    Tykocinski, Lars-Oliver
    Blank, Norbert
    Watzl, Carsten
    Schmitt, Anita
    Sauer, Tim
    Mueller-Tidow, Carsten
    Polke, Markus
    Heussel, Claus Peter
    Dreger, Peter
    Lorenz, Hanns-Martin
    Schmitt, Michael
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (04) : 543 - 546